C07D 241/00
Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
C07D241/00 (Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings) appears on 5,030 US grants and 4,907 published applications in this corpus.
Search patents in C07D- Granted patents
- 5,030
- Published applications
- 4,907
- Assignees
- 1,906
- Inventors
- 14,386
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 63 | 0 |
| 1977 | 36 | 0 |
| 1978 | 43 | 0 |
| 1979 | 34 | 0 |
| 1980 | 44 | 0 |
| 1981 | 41 | 0 |
| 1982 | 36 | 0 |
| 1983 | 30 | 0 |
| 1984 | 50 | 0 |
| 1985 | 51 | 0 |
| 1986 | 44 | 0 |
| 1987 | 74 | 0 |
| 1988 | 57 | 0 |
| 1989 | 70 | 0 |
| 1990 | 78 | 0 |
| 1991 | 48 | 0 |
| 1992 | 60 | 0 |
| 1993 | 62 | 0 |
| 1994 | 52 | 0 |
| 1995 | 52 | 0 |
| 1996 | 62 | 0 |
| 1997 | 118 | 0 |
| 1998 | 103 | 0 |
| 1999 | 113 | 0 |
| 2000 | 89 | 0 |
| 2001 | 106 | 17 |
| 2002 | 113 | 123 |
| 2003 | 103 | 183 |
| 2004 | 84 | 212 |
| 2005 | 92 | 195 |
| 2006 | 98 | 145 |
| 2007 | 97 | 157 |
| 2008 | 95 | 164 |
| 2009 | 107 | 202 |
| 2010 | 121 | 250 |
| 2011 | 127 | 208 |
| 2012 | 179 | 189 |
| 2013 | 164 | 209 |
| 2014 | 212 | 242 |
| 2015 | 220 | 244 |
| 2016 | 177 | 218 |
| 2017 | 193 | 230 |
| 2018 | 176 | 201 |
| 2019 | 174 | 224 |
| 2020 | 181 | 238 |
| 2021 | 152 | 202 |
| 2022 | 144 | 190 |
| 2023 | 107 | 231 |
| 2024 | 101 | 166 |
| 2025 | 109 | 157 |
| 2026 | 88 | 110 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof6 Oct 2026US 12,753,166 B2Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- P38alpha mitogen-activated protein kinase inhibitors6 Oct 2026US 12,753,184 B2Gen1E Lifesciences Inc.
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents22 Sep 2026US 12,740,943 B2ModernaTX, Inc.
- Inhibitors and uses thereof22 Sep 2026US 12,740,991 B2Vividion Therapeutics, Inc.
- Method for Treating Phosphorus-Containing Wastewater Produced During Preparation of Sulfonamide Compound8 Oct 2026US 2026/0308035 A1Nanhai Beisha Pharmaceutical Co., Ltd.
- Bicyclic compounds8 Oct 2026US 2026/0308114 A1Vivace Therapeutics, Inc.
- Inhibitors of JUN N-Terminal Kinases (JNK1, JNK2, and/or JNK3) and Mitogen-Activated Protein Kinases (MAPK8, MAPK9, and/or MAPK10) and Methods of Using Same1 Oct 2026US 2026/0294922 A1
- Inhibitors of spinster homolog 2 (spns2) for use in therapy1 Oct 2026US 2026/0297044 A1University of Virginia Patent Foundation
- Pyrazinecarboxamide analog compounds for use in treating cancer1 Oct 2026US 2026/0297064 A1Novapano LLC
Most cited
By later US patents
- Photodecomposable bases and photoresist compositions470US 8,614,047 B2International Business Machines Corporation · 2013
- Electrochromic compounds298US 5,998,617 AGentex Corporation · 1999
- Lipids and compositions for intracellular delivery of biologically active compounds247US 8,691,750 B2Axolabs GmbH · 2014
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases232US 6,180,632 B2Aventis Pharmaceuticals Products Inc. · 2001
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996